Job | Kyverna Therapeutics Platform & Pipeline Opportunity CAR T-Cell Therapy Pipeline Clinical Trials and Expanded Access Patients Experience Stiff Person Syndrome Myasthenia Gravis Multiple Sclerosis Lupus Nephritis Systemic Sclerosis Inside Kyverna Leadership Mission & Values Education & Events Publications Videos Investors News Careers Contact --> ← Back Executive Director, Regulatory Affairs Remote Regulatory Affairs Full Time The Executive Director, Regulatory Affairs will provide strategic and operational regulatory leadership across Kyverna's cell therapy portfolio, with a focus on commercial readiness, labeling strategy, and health authority engagement. The ideal candidate is a seasoned regulatory leader with deep experience in advanced therapies who can shape regulatory strategy from early development through approval and launch, while partnering closely with Clinical, CMC, Commercial, Market Access, and Legal teams. The Executive Director will define and execute global regulatory strategy to support clinical development, registration, and commercialization of Kyverna's autoimmune cell therapies.
The role requires the ability to translate scientific and clinical data into approvable, commercially viable labeling and to lead interactions with regulatory authorities, including FDA and global counterparts. Title: Executive Director, Regulatory Affairs Location: Remote (West Coast hours preferred) Reports to : SVP, Chief Regulatory Officer
Responsibilities Lead global regulatory strategy for Kyverna's development programs, aligning clinical, CMC, and commercial objectives from early development through post-approval lifecycle management. Provide regulatory input to program governance, asset prioritization, and portfolio decisions, including scenario planning and risk mitigation. Anticipate and address regulatory challenges related to cell therapy development, manufacturing, comparability, and long-term follow-up. Serve as the primary senior regulatory interface with FDA, EMA, and other global health authorities. Lead and/or support key regulatory meetings, including INTERACT, pre-IND, End-of-Phase, pre-BLA/MAA, Advisory Committees, and post-marketing commitments. Drive regulatory negotiation strategy, including benefit-risk, endpoints, comparability, and post-approval
requirements. Own and drive labeling strategy from early development through approval, ensuring labels support commercial differentiation, patient access, and lifecycle value. Lead development of Target Product Profiles (TPPs) and ensure alignment across Clinical, Regulatory, Commercial, and Market Access. Partner with Commercial, Medical Affairs, and Market Access to ensure regulatory decisions support launch readiness, promotional strategy, and payer engagement. Lead label negotiations with health authorities, balancing scientific evidence, regulatory expectations, and commercial objectives. Oversee and contribute to the preparation, review, and submission of INDs, CTAs, BLAs/MAAs, briefing packages, orphan drug applications, and other regulatory filings. Ensure submissions are high-quality, compliant, and strategically positioned. Maintain oversight of submission timelines, dependencies, and risk management, providing clear communication to senior leadership. Act as a strategic partner to Clinical Development, CMC, Research, Commercial, Legal, BD, and Alliance Management teams. Provide regulatory due diligence and strategic input for business development, in-licensing, out-licensing, and partnership opportunities. Oversee regulatory activities performed by CROs, consultants, and partners, ensuring quality and strategic alignment. Lead, mentor, and scale a high-performing regulatory team, fostering accountability, development, and a culture of collaboration. Establish and maintain regulatory policies, procedures, and infrastructure to support a growing, late-stage organization. Stay current on US and global regulatory intelligence and communicate key implications to stakeholders.
Requirements Bachelor's degree in a scientific discipline required; advanced degree preferred. 15+ years of progressive regulatory affairs experience in pharmaceutical or biotechnology, with significant advanced therapy experience. Cell and/or gene therapy experience preferred; autoimmune disease experience highly preferred. Demonstrated success leading global regulatory strategies through late-stage development and/or approvals, ideally including BLA/MAA experience. Proven experience with labeling strategy development and negotiation, with strong understanding of commercialization impacts. Deep knowledge of FDA regulations, ICH guidelines, and global regulatory frameworks; EMA and ex-US experience preferred. Track record of effective engagement with FDA OTP and/or divisions overseeing autoimmune or immune-mediated diseases. Strong executive communication skills with the ability to influence senior leadership and Board-facing audiences. Demonstrated ability to lead and scale teams in a fast-paced, high-growth environment. Prior supervisory experience preferred. Strategic mindset with the ability to balance scientific rigor, regulatory compliance, and commercial impact. The national base salary range for this position is $270K-$300K annually. This salary range is an estimate of what we reasonably expect to pay for this position, and the actual salary may vary based on various factors that may include but are not limited to quality and length of experience, education, geographic location and alignment with market data. This position is also eligible for
bonus,
benefits, and participation in the company's stock plan. Apply for this job Links Home Platform & Pipeline Patients Inside Kyverna Education & Events Investors Careers Contact About Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead CAR T-cell therapy candidate mivocabtagene (miv-cel, KYV-101), is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff person syndrome, multiple sclerosis, and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. FOLLOW US ON SOCIAL Privacy Policy (US) Privacy Policy (EU/UK) Designed by Elegant Themes | Powered by WordPress
Salary
$270,000 - $300,000
Location
Remote
Total raised
$322.0M
Last stage
Public
Investors
Jeffrey Greve
Co-Founder
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.